After a rare win, a biotech details long-awaited results for its ALS drug

After a rare win, a biotech details long-awaited results for its ALS drug

Source: 
BioPharma Dive
snippet: 

Each point matters, according to Sabrina Paganoni, co-director of the Neurological Clinical Research Institute at Massachusetts General Hospital. It could mean the difference between legible or illegible writing, between needing help to walk and not being able to walk at all. That sensitivity, Paganoni said, is a big reason why new data published Wednesday in The New England Journal of Medicine are exciting.

The data show patients with rapidly progressing ALS who took an experimental drug called AMX0035 had better scores than those who didn't. More specifically, drug-treated patients scored an average 2.3 points higher and had slower rates of functional decline than patients given a placebo.